Cullinan Oncology has programs that span diverse technology platforms, modalities, cancer indications, and stages of development. Our programs activate immune or oncogenic targets and have the potential to be the best or first in their class.

Learn more about our programs below:

Zipalertinib CLN-081/TAS6417 is an orally available small molecule being developed in collaboration with Taiho Pharmaceutical. Zipalertinib (CLN-081/TAS6417) is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (NSCLC). Zipalertinib (CLN-081/TAS6417) is being investigated in a Phase 1/2a dose escalation and expansion trial evaluating oral, twice-daily, or BID, administration of various doses in patients with NSCLC harboring EGFRex20ins mutations, who have had at least one prior treatment with platinum-based chemotherapy or another approved standard therapy.

Cullinan Oncology CLN-081/TAS6417 2022 ASCO Poster Presentation

2022 ASCO

Cullinan Pearl 2021 ASCO Poster Presentation

2021 ASCO

Cullinan Oncology Pearl 2020 ESMO Poster Presentation

2020 ESMO

Cullinan Oncology Pearl 2019 WCLC Poster Presentation

2019 WCLC

CLN-049 is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.

Cullinan Oncology Florentine

2022 AACR

CLN-619 is a MICA/B-targeted, humanized IgG1 monoclonal antibody that is being developed for the treatment of patients with advanced malignancies. CLN-619 is designed to promote an antitumor response through multiple mechanisms of action, including engagement of NKG2D on NK and T cells to activate lysis of cancer cells and induction of antibody-dependent cellular cytotoxicity (ADCC). CLN-619 promotes immune-mediated lysis of MICA/B expressing tumor cells in vitro and exhibits robust anti-tumor efficacy in mouse xenograft models. A phase I clinical trial of CLN-619 as monotherapy and in combination with pembrolizumab is currently ongoing for the treatment of patients with advanced malignancies.

Cullinan Presentation: 2022 SITC PDF Download

2022 SITC

Cullinan Presentation at 2022 ASCO for CLN-619-MiCA

2022 ESMO

Cullinan Oncology Presentation at 2022 ASCO for CLN-619-MiCA

2022 ASCO

Cullinan Oncology Mica

2022 AACR

CLN-978 is a half-life extended, humanized, single-chain T cell engaging antibody construct designed to simultaneously engage CD19 on targeted cancer cells and CD3 on T cells, triggering redirected T cells to lyse cancer cells. Particular features of CLN-978 include a high affinity CD19 binder to enable lysis of CD19-low expressing tumor cells and a human serum albumin binding antibody domain designed to prolong serum half-life. CLN-978 is being evaluated as a novel treatment for B-cell ALL or NHL and is currently in IND-enabling studies.

Cullinan Oncology NexGem

2022 AACR

CLN-617 is a single chain fusion protein combining two antitumor cytokines, IL-2 and IL-12, with a collagen-binding domain for the treatment of solid tumors. The collagen-binding domain is designed to retain the cytokines in the tumor microenvironment following intratumoral administration, with the goal of minimizing systemic dissemination and associated toxicities of cytokines while prolonging immunostimulatory antitumor activity. By utilizing a collagen-binding domain, CLN-617 has the potential to address the shortcomings of current systemic cytokine administration and making it the only anti-cancer therapeutic candidate in development that we are aware of that combines IL-2 and IL-12.

Cullinan CLN-617 SITC 2022 Poster

2022 SITC

Cullinan Oncology Amber

2022 AACR

PD-1 x CD137L fusion protein is a bispecific fusion protein designed to selectively activate the 4-IBB/CD137 pathway on T cells in tumors and simultaneously block PD-1 binding to PDL-1 and PDL-2. PD-1 x CD137L fusion protein is currently undergoing lead selection.

Cullinan Oncology Opal

2022 AACR